Clinical trials: Semaglutide
Diabetes, Diabetes Mellitus, Type 2
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.
- Trial name
- NCT01923181
- Testing
- semaglutide
- Where
- 103 sites in United States, Austria and 12 more
- Volunteers
- 632 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 6 (NCT03811574)
- Testing
- Semaglutide
- Where
- 28 sites in Japan, South Korea
- Volunteers
- 401 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of the trial is to investigate safety and efficacy of semaglutide once weekly in monotherapy or in combination with one OAD (oral anti-diabetic drug) in Japanese subjects with type 2…
- Trial name
- SUSTAIN™ (NCT02207374)
- Testing
- semaglutide, DPP-4 inhibitor
- Where
- 43 sites in Japan
- Volunteers
- 601 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide once weekly versus placebo as add-on to basal insulin alone or basal…
- Trial name
- SUSTAIN™ 5 (NCT02305381)
- Testing
- semaglutide
- Where
- 99 sites in United States, Germany and 4 more
- Volunteers
- 397 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 2 (NCT02863328)
- Testing
- semaglutide, empagliflozin
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 822 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes.
- Trial name
- REALYSE (NCT05035082)
- Testing
- semaglutide, oral glucose-lowering medications (commercially available)
- Where
- 25 sites in United States
- Volunteers
- 1,018 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral…
- Trial name
- SUSTAIN 8 (NCT03136484)
- Testing
- Semaglutide, Canagliflozin
- Where
- 119 sites in United States, Argentina and 10 more
- Volunteers
- 788 people
- Sponsor
- Novo Nordisk A/S
Tobacco Use Disorder, Nicotine Addiction
Effects of Semaglutide on Nicotine Intake
Tobacco use remains the foremost cause of preventable deaths in the U.S. and worldwide. Advancing new smoking cessation therapies, including those targeting novel biological mechanisms, is a critical public health priority.
- Trial name
- NCT05530577
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Overweight, Obesity
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine.
- Trial name
- STEP 5 (NCT03693430)
- Testing
- Semaglutide
- Where
- 41 sites in United States, Canada and 3 more
- Volunteers
- 304 people
- Sponsor
- Novo Nordisk A/S
Hepatobiliary Disorders, Non-alcoholic Steatohepatitis
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis
- Trial name
- NCT02970942
- Testing
- Semaglutide
- Where
- 158 sites in United States, Australia and 15 more
- Volunteers
- 320 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
This study is conducted in Europe. The aim of the study is to compare the effect of semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg once-daily on blood sugar levels after 30 weeks of…
- Trial name
- SUSTAIN 10 (NCT03191396)
- Testing
- Semaglutide, Liraglutide
- Where
- 92 sites in Bulgaria, Czechia and 10 more
- Volunteers
- 577 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e.
- Trial name
- SUSTAIN™ 6 (NCT01720446)
- Testing
- semaglutide
- Where
- 253 sites in United States, Algeria and 19 more
- Volunteers
- 3,297 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone.
- Trial name
- NCT04982575
- Testing
- Semaglutide 2.4 mg, Cagrilintide 2.4 mg
- Where
- 23 sites in United States
- Volunteers
- 92 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy"…
- Trial name
- NCT04102189
- Testing
- Semaglutide
- Where
- 51 sites in United States, Austria and 6 more
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
HIV/AIDS, Lipohypertrophy
Effects of Semaglutide in HIV-Associated Lipohypertrophy
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream…
- Conditions
- HIV/AIDS, Lipohypertrophy, Obesity
- Trial name
- NCT04019197
- Testing
- Semaglutide Injectable Product
- Where
- 2 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
Diabetes, Diabetes Mellitus, Type 2
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
- Trial name
- NCT02461589
- Testing
- semaglutide, liraglutide
- Where
- 150 sites in United States, Austria and 8 more
- Volunteers
- 706 people
- Sponsor
- Novo Nordisk A/S
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Semaglutide in CFRD
This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).
- Trial name
- NCT05788965
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 2
A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered.
- Trial name
- NCT03724981
- Testing
- Dulaglutide Pen, Semaglutide Pen
- Where
- 14 sites in United States
- Volunteers
- 312 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers, Diabetes Mellitus, Type 2
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin).
- Conditions
- Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity
- Trial name
- NCT04189848
- Testing
- Semaglutide, Dulaglutide
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Alcohol Use Disorder, Cigarette Smoking
Semaglutide for Alcohol Use Disorder
This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol…
- Trial name
- NCT05520775
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill